Archives of the Turkish Society of Cardiology
Novel agents in antiplatelet therapy [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2010; 38(5): 369-378

Novel agents in antiplatelet therapy

Mehmet Ağırbaşlı, Hacer Güvenç, Altuğ Çinçin
Marmara University Medical School, Department of Cardiology, Istanbul, Turkey

Antiplatelet therapy is the cornerstone of management of acute coronary syndromes. Currently used antiplatelet drugs present several limitations that provoke new searches. These limitations include resistance, delay in the onset of action, risk for bleeding, variations in the individual response, and interaction with other medications (i.e. proton pump inhibitors, calcium channel blockers). New concepts and medications have emerged for the effective inhibition of platelets. Prasugrel, AZD6140 (ticagrelor), cangrelor, and SCH 530348 (thrombin receptor antagonist) are among some of the novel agents that survived randomized trials. In this review, we aimed to summarize novel concepts and agents in antiplatelet therapy.

Keywords: Acute coronary syndrome/drug therapy, platelet aggregation/drug effects, platelet aggregation inhibitors

How to cite this article
Mehmet Ağırbaşlı, Hacer Güvenç, Altuğ Çinçin. Novel agents in antiplatelet therapy. Turk Kardiyol Dern Ars. 2010; 38(5): 369-378

Corresponding Author: Mehmet Ağırbaşlı, Türkiye
© Copyright 2020 Archives of the Turkish Society of Cardiology
LookUs & Online Makale